NCT07484022 2026-03-19Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial CancerGenerate BiomedicinesPhase 1 Not yet recruiting37 enrolled
NCT03098589 2025-03-30Revlimid® Capsules Drug Use-results Surveillance (Relapsed or Refractory ATLL)CelgeneCompleted1,149 enrolled